$Zomedica Pharmaceuticals Corp.(ZOM)$

Believe in what you invest in...

“Zomedica recorded net loss and comprehensive loss for the year ended December 31, 2020 of approximately $16.9 million or $0.05 per share, compared to a loss of approximately $19.8 million or $0.19 per share for the year ended December 31, 2019”.

This stock didn’t have any revenue in 2020 but they still managed to beat 2019 loss? Why? They did well on research and investing. Now that they’re releasing TRUFORMA changes the tide in the market.

Veterinary Diagnostics is a growing market and I see ZOM being one of the biggest competitor with their product. Why?

· Enhanced capability to detect the frequency of occurrence and severity of diseases and conditions that impact companion animals;

· Increased accuracy and faster means to obtain test results;

· Wider availability of new diagnostic tools; and

· Enhanced economic benefits for veterinarians